AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
10.66
+0.19 (1.81%)
At close: Apr 15, 2026, 4:00 PM EDT
10.60
-0.06 (-0.56%)
After-hours: Apr 15, 2026, 4:42 PM EDT
AgomAb Therapeutics NV Employees
AgomAb Therapeutics NV had 58 employees as of December 31, 2024. The number of employees increased by 24 or 70.00% compared to the previous year.
Employees
58
Change
24
Growth
70.00%
Revenue / Employee
n/a
Profits / Employee
-$1,466,924
Market Cap
519.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 58 | 24 | 70.00% |
| Dec 31, 2023 | 34 | 33 | 3,300.00% |
| Dec 31, 2019 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| 4D Molecular Therapeutics | 196 |
| Allogene Therapeutics | 152 |
| Entrada Therapeutics | 152 |
| enGene Therapeutics | 82 |
| Upstream Bio | 75 |
| Larimar Therapeutics | 71 |
| Lexeo Therapeutics | 59 |
AGMB News
- 20 days ago - Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 2 months ago - Agomab Announces Closing of Initial Public Offering - GlobeNewsWire
- 2 months ago - Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut - Reuters
- 2 months ago - Agomab Announces Pricing of Initial Public Offering - GlobeNewsWire
- 3 months ago - Agomab Therapeutics files for US IPO - Reuters
- 3 months ago - AgomAb Therapeutics IPO Registration Document (F-1) - SEC